Literature DB >> 17691408

The role of spinal cord stimulation in the management of patients with brain tumors.

F Robaina1, B Clavo.   

Abstract

High grade gliomas (HGG) have decreased blood flow resulting in hypoxia, limited access by chemotherapeutic agents, and reduced radiation-sensitivity. Spinal cord stimulation (SCS) has been used successfully in the treatment of pain and ischemic syndromes. The present article summarizes our investigations into the effects of SCS in patients with HGG. Before their scheduled radio-chemotherapy, 23 patients with HGG were assessed pre- and post-SCS using several evaluation techniques: (1) transcranial Doppler (TCD) for middle cerebral artery blood flow; (2) color Doppler for common carotid artery blood flow; (3) single photon emission computed tomography (SPECT) for tumor blood flow; (4) polarographic probe technique for tumor pO2 measurement; (5) positron emission tomography (PET) for tumor glucose metabolism. Pre-SCS, the tumors were more ischemic and more hypoxic than healthy tissues. Post-SCS, there was significant: (1) increase in blood flow measured by TCD (> or =18%), color Doppler (> or =61%) and SPECT (15%), (2) increase in oxygenation and decrease (> or =45%) in percentage of hypoxic values <10 mmHg and <5 mmHg, and (3) increase (43%) in glucose metabolism. Our studies show that SCS can modify loco-regional blood flow and oxygen supply, as well as glucose-metabolism in HGG. This suggests that SCS could prove useful as an adjuvant treatment to radio-chemotherapy. These data merit further confirmatory studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691408     DOI: 10.1007/978-3-211-33079-1_58

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  2 in total

1.  Modulation of neuronal activity in dorsal column nuclei by upper cervical spinal cord stimulation in rats.

Authors:  C Qin; X Yang; M Wu; J P Farber; B Linderoth; R D Foreman
Journal:  Neuroscience       Date:  2009-08-07       Impact factor: 3.590

Review 2.  Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted?

Authors:  Bernardino Clavo; Norberto Santana-Rodríguez; Pedro Llontop; Dominga Gutiérrez; Gerardo Suárez; Laura López; Gloria Rovira; Gregorio Martínez-Sánchez; Esteban González; Ignacio J Jorge; Carmen Perera; Jesús Blanco; Francisco Rodríguez-Esparragón
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-09       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.